An interventional study of Osteopathic manipulative treatment and No intervention in Low Back Pain, sponsored by Michigan State University. Terminated at 3 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Michigan State University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.
Among the 712 studies in Low Back Pain with a site in United States, this one is the 285th largest by enrollment of the 623 interventional ones that give a count, is one of 35 that started in 2015, is one of 408 with no phase, and was the 284th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
New York Medical College · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–65 · Healthy volunteers
University of Central Florida · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
712 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 80 · Phase 3 73 · Phase 4 50
First in 1977; this study’s year is marked. 35 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 79 across the 623 interventional studies, 90 across the 85 observational. Of the 513 that completed or were terminated, 207 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 712 have an industry lead sponsor. The 10 most frequent:
Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.
Michigan State University has 2 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
52 of the studies in Low Back Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07652944Joe X. ZhangTrial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain. | 2026-11 |
| NCT04730700University of Kansas Medical CenterEvaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. | 2026-11-30 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 52 to your calendar (.ics) → With an account.
Among the 712 studies in Low Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall goal of this project is to develop sensitive and objective clinical research tools for the assessment of postural control of the trunk. In order to accomplish this goal, we aim to quantify balance performance in an unstable seated task. Specifically, the investigators will quantify balance performance in low back pain participants before and after osteopathic manipulative treatment. The investigators hypothesize that there will be a significant improvement in balance performance after a single session of osteopathic manipulative treatment as well as after 4 sessions of osteopathic manipulative treatment and this improvement will be greater than any learning effect.
A secondary objective of this study is to quantify differences in patient-oriented outcome measures (e.g., self-reported pain, disability) in low back pain participants before and after osteopathic manipulative treatment. The investigators hypothesize that there will be a significant improvement in these self-reported outcomes following osteopathic manipulative treatment. The association between improvement in postural control parameters and patient-oriented measures will also be explored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants must meet all of the inclusion criteria to participate in the study. Below is a list of inclusion criteria for LBP participants:
Exclusion Criteria:
All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. Exclusion criteria will be self-reported. However, during each treatment session, the physicians will be watching for clinical signs and symptoms not consistent with physical findings that are suggestive of the presence of any of the exclusion criteria. In such a case, further treatment will be discontinued and the subject will be excluded.
Below is a list of exclusion criteria:
History of:
Unresolved symptoms from:
Current diagnosis of:
Conditions recognized by a physician any time during the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week), then received no intervention after for approximately 4 weeks.
Procedure: Osteopathic manipulative treatment · Other: No intervention
This arm received no intervention after for approximately 4 weeks, then received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week).
Procedure: Osteopathic manipulative treatment · Other: No intervention
Up to 4 sessions of osteopathic manipulative treatment (once per week)
No interventions for approximately 4 weeks
Postural Control
Postural control will be assessed in an unstable seated task, in which subjects will be asked to balance on a specially designed seat that wobbles side to side. Participant will be asked to maintain their upright posture while keeping their eyes open. The root mean square error (difference between the trunk angle from their upright position) is computed then converted to Z-score based the study populations' baseline mean and standard deviation. The score ranged from -1.67 to 2.95. Z-score of 0 indicates study population's average at the baseline. Higher Z-score indicates worse performance.
Time frame: Baseline, Week 1, Week 4 (crossover), & Week 8
Trunk Muscle Reflex Latency
Subjects will be pulling with their trunk on a cable held by an electromagnet. The electromagnet will be suddenly released. Trunk muscle response to sudden load release will be measured on electromyographical recordings.
Time frame: Baseline, Week 1, Week 4 (crossover), & Week 8
Patient Reported Outcomes Measurement Information System (PROMIS)
Assesses changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with Patient Reported Outcomes Measurement Information System (PROMIS) 29 questionnaire. Patients rated the statements in each domain from 0-5. Scores are summed for each domain (ranges from 4 to 20), and converted to T-scores using PROMIS conversion table (for details see http://www.healthmeasures.net/promis-scoring-manuals) . T-score of 50 indicates population average with a standard deviation of 10. Higher scores indicate worse outcomes for pain interference, sleep disturbance, fatigue, depression, and anxiety; whereas higher scores indicate better outcomes for physical function and Satisfaction with participation in social roles.
Time frame: Baseline and Week 4 (crossover point)
Concomitant Medication
Assesses the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.
Time frame: Baseline, Week 4 (crossover), Week8
Oswestry Disability Index
Assesses changes in functional activities related to low back disability with the Oswestry Disability Index questionnaire. Patients selected statements that best described their condition from 10 domains affecting daily life. Each domain is scored from 0 (no disability) to 5 (highest disability). Scores from each domains are summed then percentages are calculated out of 50. Higher percentage is associated with higher disability.
Time frame: Baseline, Week 4 (crossover), and Week 8
Fear Avoidance Beliefs Questionnaire
The Fear Avoidance Beliefs questionnaire (FABQ) assesses effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).
Time frame: Baseline, Week 4 (crossover), and Week 8
Participants were recruited from general population in the Greater Lansing area between May 2015 to June 2018.
| Milestone | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Started | 40 | 40 |
| Visit 1 - patient reported outcome (baseline) | 40 | 40 |
| Visit 1 - biomechanical testing (baseline) | 40 | 39 |
| Visit 2 - patient reported outcome | 35 | 36 |
| Visit 2 - biomechanical testing | 34 | 34 |
| Visit 3 - patient reported outcome (crossover) | 31 | 33 |
| Visit 3 - biomechanical testing (crossover) | 31 | 33 |
| Visit 4 - patient reported outcome | 30 | 33 |
| Visit 4 - biomechanical testing | 30 | 33 |
| Completed | 30 | 33 |
| Not completed | 10 | 7 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Withdrawal by subject | 8 | 4 |
Postural control will be assessed in an unstable seated task, in which subjects will be asked to balance on a specially designed seat that wobbles side to side. Participant will be asked to maintain their upright posture while keeping their eyes open. The root mean square error (difference between the trunk angle from their upright position) is computed then converted to Z-score based the study populations' baseline mean and standard deviation. The score ranged from -1.67 to 2.95. Z-score of 0 indicates study population's average at the baseline. Higher Z-score indicates worse performance.
| Z-score | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Baseline - Eyes Open Root mean square error (RMSE) | -0.07 ± 0.93 | 0.09 ± 1.11 |
| Week 1- Eyes Open RMSE | 0.01 ± 0.99 | 0.04 ± 0.84 |
| Week 4- Eyes Open RMSE | 0.10 ± 0.94 | -0.13 ± 0.90 |
| Week 8 - Eyes Open RMSE | -0.10 ± 0.95 | -0.04 ± 0.99 |
Subjects will be pulling with their trunk on a cable held by an electromagnet. The electromagnet will be suddenly released. Trunk muscle response to sudden load release will be measured on electromyographical recordings.
| millisecond | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Baseline- Back muscle shut-off latency | 106.26 ± 59.75 | 103.04 ± 63.88 |
| Week 1- Back muscle shut-off latency | 101.63 ± 61.89 | 73.62 ± 49.13 |
| Week 4 - Back muscle shut-off latency | 106.97 ± 63.34 | 91.00 ± 51.73 |
| Week 8 - Back muscle shut-off latency | 125.12 ± 55.47 | 91.08 ± 46.44 |
Assesses changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with Patient Reported Outcomes Measurement Information System (PROMIS) 29 questionnaire. Patients rated the statements in each domain from 0-5. Scores are summed for each domain (ranges from 4 to 20), and converted to T-scores using PROMIS conversion table (for details see http://www.healthmeasures.net/promis-scoring-manuals) . T-score of 50 indicates population average with a standard deviation of 10. Higher scores indicate worse outcomes for pain interference, sleep disturbance, fatigue, depression, and anxiety; whereas higher scores indicate better outcomes for physical function and Satisfaction with participation in social roles.
| T-score | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Baseline - Pain interference | 62.86 ± 5.03 | 60.36 ± 5.21 |
| Week 4 - Pain interference | 62.13 ± 6.91 | 58.51 ± 5.99 |
| Baseline - Satisfaction with participation in social roles | 42.35 ± 6.37 | 46.45 ± 5.51 |
| Week 4 - Satisfaction with participation in social roles | 42.09 ± 7.41 | 43.01 ± 7.59 |
| Baseline - Sleep disturbance | 56.75 ± 9.13 | 52.92 ± 6.64 |
| Week 4 - Sleep disturbance | 53.81 ± 8.86 | 53.80 ± 7.95 |
| Baseline - Fatigue | 56.39 ± 9.66 | 54.26 ± 8.18 |
| Week 4 - Fatigue | 55.91 ± 10.73 | 55.47 ± 9.58 |
| Baseline - Depression | 48.57 ± 7.83 | 49.13 ± 7.84 |
| Week 4 - Depression | 45.91 ± 7.03 | 48.71 ± 9.08 |
| Baseline - Anxiety | 53.81 ± 8.38 | 49.68 ± 8.44 |
| Week 4 - Anxiety | 47.37 ± 7.99 | 49.60 ± 8.94 |
| Baseline - Physical function | 39.74 ± 4.29 | 43.21 ± 6.73 |
| Week 4 - Physical function | 40.03 ± 5.12 | 42.08 ± 5.89 |
Assesses the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.
| Number of medication | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Baseline | 2.8 ± 4.8 | 2.6 ± 3.8 |
| Week 4 | 2.1 ± 4.9 | 2.5 ± 4.1 |
| Week 8 | 2.4 ± 5.0 | 1.9 ± 2.4 |
Assesses changes in functional activities related to low back disability with the Oswestry Disability Index questionnaire. Patients selected statements that best described their condition from 10 domains affecting daily life. Each domain is scored from 0 (no disability) to 5 (highest disability). Scores from each domains are summed then percentages are calculated out of 50. Higher percentage is associated with higher disability.
| % (out of 50) | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Baseline | 34.8 ± 12.0 | 29.6 ± 10.3 |
| Week 4 | 31.9 ± 12.0 | 29.1 ± 13.4 |
| Week 8 | 29.4 ± 13.2 | 28.0 ± 12.3 |
The Fear Avoidance Beliefs questionnaire (FABQ) assesses effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).
| scores on a scale | OMT First, Then No Intervention | No Intervention, Then OMT |
|---|---|---|
| Baseline - FABQ-Work | 15.8 ± 10.1 | 11.8 ± 9.3 |
| Week 4 - FABQ-Work | 13.6 ± 11.0 | 11.2 ± 8.8 |
| Baseline - FABQ-Physical Activity | 14.7 ± 5.0 | 12.9 ± 5.2 |
| Week 4 - FABQ-Physical Activity | 15.5 ± 4.2 | 12.5 ± 5.2 |
| Week 8 - FABQ-Work | 15.3 ± 11.2 | 11.7 ± 9.6 |
| Week 8 - FABQ-Physical Activity | 15.0 ± 4.2 | 12.2 ± 6.1 |
Collected over Baseline - Week 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Osteopathic Manipulative Treatment (OMT) | 0/73 (0%) | 0/73 (0%) | 39/73 (53.4%) |
| No Intervention | 0/71 (0%) | 1/71 (1.4%) | 15/71 (21.1%) |
| Event | Osteopathic Manipulative Treatment (OMT) | No Intervention |
|---|---|---|
| ColitisGastrointestinal disorders | 0/73 | 1/71 |
| Event | Osteopathic Manipulative Treatment (OMT) | No Intervention |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 26/73 | 9/71 |
| MyalgiaMusculoskeletal and connective tissue disorders | 18/73 | 2/71 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/73 | 3/71 |
| Muscle fatigueMusculoskeletal and connective tissue disorders | 5/73 | 3/71 |
| Age, Categorical(Participants) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 39 | 40 | 79 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| Female | 24 | 25 | 49 |
| Male | 16 | 15 | 31 |
| Race (NIH/OMB)(Participants) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 26 | 33 | 59 |
| More than one race | 4 | 1 | 5 |
| Unknown or Not Reported | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 35 | 37 | 72 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| United States | 40 | 40 | 80 |
| Average Pain(units on a scale) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| Mean | 5.98 ± 1.75 | 5.80 ± 1.83 | 5.89 ± 1.78 |
| Oswestry Disability Index (OSW)(%) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| Mean | 35.3 ± 11.8 | 30.7 ± 10.6 | 33.0 ± 11.4 |
| Fear Avoidance Belief Questionnaire (FABQ)(units on a scale) | OMT First, Then No Intervention | No Intervention, Then OMT | Total |
|---|---|---|---|
| Work (out of 42) | 17.33 ± 10.46 | 11.80 ± 8.68 | 14.56 ± 9.95 |
| Physical Activity (out of 24) | 14.75 ± 4.86 | 13.00 ± 5.25 | 13.88 ± 5.1 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Aug 2018, 38 months.
Results were first posted in Nov 2026, 8 years 2 months after primary completion.
Start moved once since we started tracking on Sep 25, 2026: Apr 2014 → Jun 2015, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.